Dietary Supplements: Safety, Efficacy, and Regulation in the US

The dietary supplement industry in the United States generates over $50 billion in annual sales (Council for Responsible Nutrition, 2023 CRN Consumer Survey), yet the products on those shelves occupy a regulatory category unlike any other consumer health product. This page covers how supplements are defined under federal law, what the FDA can and cannot require of manufacturers before a product reaches market, what the science actually shows about efficacy, and where the genuine tensions in the field lie. The gap between what most people assume about supplement oversight and what the law actually requires is, to put it plainly, substantial.

• Definition and scope
• Core mechanics or structure
• Causal relationships or drivers
• Classification boundaries
• Tradeoffs and tensions
• Common misconceptions
• Checklist or steps
• Reference table or matrix

Definition and scope

A dietary supplement, under the Dietary Supplement Health and Education Act of 1994 (DSHEA), is defined as a product intended to supplement the diet that contains one or more of the following: vitamins, minerals, herbs or other botanicals, amino acids, or dietary substances used to supplement the diet by increasing total dietary intake. Enzymes, organ tissues, glandulars, and metabolites are also included under this umbrella. The product must be intended for ingestion — as a tablet, capsule, softgel, gelcap, powder, or liquid — and must be labeled as a dietary supplement.

That label does a great deal of regulatory work. The moment a product carries it, it exits the drug approval framework entirely. Supplements are legally positioned as a subcategory of food, not as pharmaceuticals. This is not a regulatory loophole discovered after the fact — it was the explicit design of DSHEA, passed by Congress in 1994 following an industry campaign that generated more constituent mail than any piece of legislation up to that point, according to accounts documented by the FDA's own history of the Act.

The scope is wide. The FDA estimates more than 80,000 dietary supplement products are on the market in the United States (FDA Dietary Supplements Guidance), a figure that has grown from roughly 4,000 products at the time DSHEA passed.

Core mechanics or structure

The structural centerpiece of US supplement regulation is a pre-market/post-market asymmetry. For a pharmaceutical drug, the manufacturer must demonstrate safety and efficacy to the FDA before the product can be sold. For a dietary supplement, the burden flips: the FDA must demonstrate that a product is unsafe after it is already on the market before taking action to remove it.

Manufacturers are required to notify the FDA at least 75 days before marketing any supplement containing a "new dietary ingredient" — one not marketed in the US before October 15, 1994 (21 CFR Part 190). That notification must include information about why the manufacturer believes the ingredient is reasonably expected to be safe. It is not an approval process; it is a notification with a response window.

Current Good Manufacturing Practice (CGMP) regulations, codified at 21 CFR Part 111, require supplement manufacturers to verify identity, purity, strength, and composition of finished products. These rules, finalized in 2007, brought real structure to manufacturing. However, FDA inspections of supplement facilities are resource-constrained, and third-party audits are voluntary unless a company opts into a certification program such as those offered by NSF International, USP (United States Pharmacopeia), or ConsumerLab.

Labeling rules allow structure/function claims — statements like "supports immune health" or "promotes bone strength" — without FDA pre-approval, provided the manufacturer notifies the FDA within 30 days of marketing and includes the disclaimer: "This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease" (21 CFR 101.93).

Causal relationships or drivers

The nutrient insufficiency picture in the US creates genuine demand. The National Health and Nutrition Examination Survey (NHANES), conducted by the CDC, has documented that a significant portion of Americans fall below the Estimated Average Requirement for vitamin D, calcium, potassium, and magnesium from food alone. For vitamin D specifically, NHANES data have shown that roughly 40% of US adults have serum 25-hydroxyvitamin D levels below 50 nmol/L — a threshold some clinical organizations flag as insufficient.

This population-level insufficiency is real, and it creates a rational driver for supplementation in specific contexts: older adults with reduced sun exposure, people with documented malabsorption conditions, pregnant individuals requiring folate and iron at levels difficult to obtain from diet alone (as addressed in prenatal and postpartum nutrition), and populations with restricted dietary patterns.

The evidentiary picture for many popular supplements diverges sharply from market size. Omega-3 fatty acids, one of the top-selling supplement categories, have a substantial body of research examined in detail at omega-3 fatty acids and fish oil. Protein supplements occupy another well-studied corner, explored at protein supplements review. Outside these better-researched categories, efficacy data thin out quickly.

Classification boundaries

The regulatory line between a supplement and a drug is drawn by intended use, not by ingredient. The same substance can be classified differently depending on how it is labeled and marketed. Melatonin sold as a sleep support supplement is regulated as a dietary supplement in the US; the identical molecule sold to treat a specific disorder would be regulated as a drug.

This creates a boundary enforcement problem. Products marketed as supplements but making implicit disease claims — or spiked with undisclosed pharmaceutical compounds — are technically illegal under DSHEA, but detection is reactive. The FDA's Tainted Supplement Database has verified hundreds of products found to contain undisclosed active drug ingredients, concentrated in categories such as weight loss, sexual enhancement, and bodybuilding.

Supplements also sit separately from functional foods and medical foods, both of which carry distinct regulatory frameworks. The broader landscape of micronutrients — vitamins and minerals consumed through diet — exists outside the supplement classification entirely.

Tradeoffs and tensions

The central tension in US supplement policy is legible from the National Nutrition Authority's home reference: the question of how much pre-market gatekeeping serves public health versus how much it restricts access to products that may offer genuine benefit.

Proponents of the current DSHEA framework argue that pre-market drug-style approval would eliminate affordable supplements used by millions who have real nutrient gaps, and that the evidence bar appropriate for pharmaceuticals treating disease is not the right standard for food-category products. Opponents point to documented harms — including liver toxicity cases linked to green tea extract and kava, and cardiac events associated with stimulant-containing pre-workouts — as evidence that the post-market-only enforcement model is inadequate.

The FTC governs advertising claims for supplements separately from FDA labeling rules, and the two agencies do not always coordinate seamlessly. A company can face FTC action for a claim in an advertisement while simultaneously complying with FDA structure/function claim rules on its label.

Third-party certification programs attempt to fill the verification gap. NSF Certified for Sport, USP Verified, and Informed Sport provide testing against label claims and screening for contaminants or banned substances — but these are industry-funded, voluntary, and cover a small fraction of the total market.

Common misconceptions

"Natural means safe." Pyrrolizidine alkaloids, aristolochic acid, and certain high-dose fat-soluble vitamins are all naturally derived and all capable of causing serious organ damage. The FDA has documented multiple cases of acute liver failure linked to botanical supplements sold without any synthetic adulterants.

"FDA approves supplements before they're sold." It does not. The pre-market notification for new dietary ingredients is not an approval. The FDA only acts after a product is on the market and a problem has been demonstrated.

"If it's in the store, the label claims are verified." Structure/function claims require no independent substantiation to reach a shelf. Manufacturers must hold substantiation on file, but that substantiation is not submitted to or reviewed by the FDA prior to sale.

"More is always better for vitamins." Upper Tolerable Intake Levels (ULs) exist for 24 nutrients as established by the National Academies of Sciences, Engineering, and Medicine. Vitamin A toxicity from supplement overuse is a documented clinical phenomenon; excessive vitamin B6 intake has been associated with peripheral neuropathy.

"Supplements can replace a balanced diet." The Dietary Guidelines for Americans, issued jointly by USDA and HHS, state consistently across editions that nutrients from foods cannot be fully replicated by supplementation because whole foods contain a matrix of compounds that interact synergistically.

Checklist or steps

The following describes the pathway a dietary supplement product travels from concept to consumer shelf under current US federal rules:

1. Ingredient sourcing and identity testing — Raw materials must be identified against specifications under CGMP rules (21 CFR Part 111).
2. New Dietary Ingredient (NDI) determination — Manufacturer determines whether any ingredient was absent from the market before October 15, 1994. If so, a 75-day pre-market notification to FDA is required.
3. Formulation and in-process testing — Blend uniformity, potency, and purity are tested at defined intervals.
4. Finished product testing — Final product is tested for identity, composition, and contamination before release.
5. Label review — Label must comply with FDA regulations including Supplement Facts panel requirements and the structure/function claim disclaimer if applicable (21 CFR 101.36).
6. Structure/function claim notification — If the label carries a structure/function claim, the manufacturer notifies FDA within 30 days of first marketing.
7. Adverse event reporting — Serious adverse events must be reported to FDA under the Dietary Supplement and Nonprescription Drug Consumer Protection Act of 2006 (21 CFR Part 111 Subpart P).
8. Post-market surveillance — FDA monitors MedWatch reports, conducts facility inspections, and may issue warning letters or initiate recalls if safety signals emerge.

Reference table or matrix

Dietary Supplement Regulatory Framework at a Glance

Third-Party Certification Programs Compared